Cargando…
PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429262/ http://dx.doi.org/10.1097/01.HS9.0000850072.95751.61 |
| _version_ | 1784779385624068096 |
|---|---|
| author | Raffoux, E. De Botton, S. Ades, L. Carré, M. Cluzeau, T. Saillard, C. Heiblig, M. Beckerich, F. Gastaud, L. Dupuis, A. Richez, U. Dumas, P.-Y. |
| author_facet | Raffoux, E. De Botton, S. Ades, L. Carré, M. Cluzeau, T. Saillard, C. Heiblig, M. Beckerich, F. Gastaud, L. Dupuis, A. Richez, U. Dumas, P.-Y. |
| author_sort | Raffoux, E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429262 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94292622022-08-31 PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY Raffoux, E. De Botton, S. Ades, L. Carré, M. Cluzeau, T. Saillard, C. Heiblig, M. Beckerich, F. Gastaud, L. Dupuis, A. Richez, U. Dumas, P.-Y. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429262/ http://dx.doi.org/10.1097/01.HS9.0000850072.95751.61 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Raffoux, E. De Botton, S. Ades, L. Carré, M. Cluzeau, T. Saillard, C. Heiblig, M. Beckerich, F. Gastaud, L. Dupuis, A. Richez, U. Dumas, P.-Y. PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY |
| title | PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY |
| title_full | PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY |
| title_fullStr | PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY |
| title_full_unstemmed | PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY |
| title_short | PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY |
| title_sort | pb1805: insights from oral azacitidine early access program in france: patient population with acute myeloid leukemia receiving oral-aza for maintenance of complete remission after induction chemotherapy |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429262/ http://dx.doi.org/10.1097/01.HS9.0000850072.95751.61 |
| work_keys_str_mv | AT raffouxe pb1805insightsfromoralazacitidineearlyaccessprograminfrancepatientpopulationwithacutemyeloidleukemiareceivingoralazaformaintenanceofcompleteremissionafterinductionchemotherapy AT debottons pb1805insightsfromoralazacitidineearlyaccessprograminfrancepatientpopulationwithacutemyeloidleukemiareceivingoralazaformaintenanceofcompleteremissionafterinductionchemotherapy AT adesl pb1805insightsfromoralazacitidineearlyaccessprograminfrancepatientpopulationwithacutemyeloidleukemiareceivingoralazaformaintenanceofcompleteremissionafterinductionchemotherapy AT carrem pb1805insightsfromoralazacitidineearlyaccessprograminfrancepatientpopulationwithacutemyeloidleukemiareceivingoralazaformaintenanceofcompleteremissionafterinductionchemotherapy AT cluzeaut pb1805insightsfromoralazacitidineearlyaccessprograminfrancepatientpopulationwithacutemyeloidleukemiareceivingoralazaformaintenanceofcompleteremissionafterinductionchemotherapy AT saillardc pb1805insightsfromoralazacitidineearlyaccessprograminfrancepatientpopulationwithacutemyeloidleukemiareceivingoralazaformaintenanceofcompleteremissionafterinductionchemotherapy AT heibligm pb1805insightsfromoralazacitidineearlyaccessprograminfrancepatientpopulationwithacutemyeloidleukemiareceivingoralazaformaintenanceofcompleteremissionafterinductionchemotherapy AT beckerichf pb1805insightsfromoralazacitidineearlyaccessprograminfrancepatientpopulationwithacutemyeloidleukemiareceivingoralazaformaintenanceofcompleteremissionafterinductionchemotherapy AT gastaudl pb1805insightsfromoralazacitidineearlyaccessprograminfrancepatientpopulationwithacutemyeloidleukemiareceivingoralazaformaintenanceofcompleteremissionafterinductionchemotherapy AT dupuisa pb1805insightsfromoralazacitidineearlyaccessprograminfrancepatientpopulationwithacutemyeloidleukemiareceivingoralazaformaintenanceofcompleteremissionafterinductionchemotherapy AT richezu pb1805insightsfromoralazacitidineearlyaccessprograminfrancepatientpopulationwithacutemyeloidleukemiareceivingoralazaformaintenanceofcompleteremissionafterinductionchemotherapy AT dumaspy pb1805insightsfromoralazacitidineearlyaccessprograminfrancepatientpopulationwithacutemyeloidleukemiareceivingoralazaformaintenanceofcompleteremissionafterinductionchemotherapy |